Oral Session 3-8B ATL: Treatment

[OS3-8B-6] Influence of defective HTLV-1 provirus on allogeneic HSCT in ATL: analyses of the ATL-NST trials

Kosuke Toyoda^1,2, Jun-Ichiro Yasunaga², Ilseung Choi³, Youko Suehiro^3,4, Naokuni Uike⁵, Jun Okamura⁶, Masao Matsuoka^1,2 (1.Virus Control, IFLMS, Kyoto University, Kyoto, Japan, 2.Hematology, Rheumatology and Infectious Diseases, Kumamoto University, Kumamoto, Japan, 3.Hematology, National Kyushu Cancer Center, Fukuoka, Japan, 4.Cell Therapy, National Kyushu Cancer Center, Fukuoka, Japan, 5.Palliative Care, Saga-ken Medical Center Koseikan, Saga, Japan, 6.Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan)